Know Cancer

or
forgot password

The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection


Phase 4
20 Years
N/A
Not Enrolling
Both
Helicobacter Pylori Infection

Thank you

Trial Information

The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection


Inclusion Criteria:



1. aged greater than 20 years who have persistent H. pylori infection after two treatments
and are willing to receive third line rescue regimens.

Exclusion Criteria:

1. children and teenagers aged less than 20 years,

2. history of gastrectomy,

3. gastric malignancy, including adenocarcinoma and lymphoma,

4. previous allergic reaction to antibiotics (Amolin, Klaricid, Cravit) and prompt pump
inhibitors (esomeprazole),

5. contraindication to treatment drugs,

6. pregnant or lactating women,

7. severe concurrent disease.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Eradication rate will be evaluated according to Intent-to-treat (ITT) and per-protocol (PP) analyses

Outcome Time Frame:

2009/04/20

Safety Issue:

No

Principal Investigator

Jyh-Ming Liou, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Taiwan University Hospital

Authority:

Taiwan: Department of Health

Study ID:

200901042M

NCT ID:

NCT01032655

Start Date:

April 2009

Completion Date:

March 2012

Related Keywords:

  • Helicobacter Pylori Infection
  • Helicobacter pylori
  • sequential therapy
  • susceptibility-driven
  • rescue
  • levofloxacin
  • clarithromycin
  • salvage
  • treatment failure
  • those who fail from two standard eradication therapies
  • Disease Susceptibility
  • Helicobacter Infections

Name

Location